

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Costs incurred by hospital visits and time off work will have a more significant impact on people with lower incomes. (Costs associated with elranatamab include the requirement to stay in or near the hospital after each step-up dose (until first full dose))

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Access to hospitals or treatment centres is an implementation issue, it is not an equality issue that can be addressed by NICE technology appraisal recommendations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

**Approved by Principal Technical Adviser (name):** JC Dietz

**Date:** 13/05/2025